Skip to content
OUR TECHNOLOGY
WHY INHALATION?
OUR PLATFORMS
OUR PIPELINE
FOR PARTNERS
WHAT WE DO
OUR CAPABILITIES
FOR INVESTORS
MARKET POTENTIAL
INVESTOR VALUE
OUR TEAM
LEADERSHIP TEAM
CAREERS
NEWS
CONTACT US
OUR TECHNOLOGY
WHY INHALATION?
OUR PLATFORMS
OUR PIPELINE
FOR PARTNERS
WHAT WE DO
OUR CAPABILITIES
FOR INVESTORS
MARKET POTENTIAL
INVESTOR VALUE
OUR TEAM
LEADERSHIP TEAM
CAREERS
NEWS
CONTACT US
US-Based Manufacturing
US-Based Manufacturing
Home
OUR TECHNOLOGY
Why Inhalation?
Our Platforms
Our Pipeline
FOR PARTNERS
What We Do
Our Capabilities
FOR INVESTORS
Market Potential
Investor Value
OUR TEAM
Leadership Team
Careers
News
Contact Us
Home
OUR TECHNOLOGY
Why Inhalation?
Our Platforms
Our Pipeline
FOR PARTNERS
What We Do
Our Capabilities
FOR INVESTORS
Market Potential
Investor Value
OUR TEAM
Leadership Team
Careers
News
Contact Us
News
Transpire Bio press releases
Read
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
February 24, 2026
7:00 am
ET
Read
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
January 27, 2026
7:00 am
ET
Read
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
7:00 am
ET
Read
Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation
January 6, 2026
7:00 am
ET
Read
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
December 9, 2025
7:00 am
ET
Read
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
October 15, 2025
7:00 am
ET
Read
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
September 23, 2025
7:00 am
ET
Read
Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor
June 3, 2025
7:00 am
ET
Read
Transpire Bio Announces R&D and Manufacturing Expansion
May 6, 2025
7:00 am
ET
Read
Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
January 13, 2025
8:00 am
ET
Read
Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
January 13, 2025
8:00 am
ET
Read
Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program
December 17, 2024
8:00 am
ET
Read
Transpire Bio Announces Corporate Office Expansion
November 12, 2024
8:00 am
ET
Read
Transpire Bio Strengthens Its Leadership Team with a New Senior-Level Appointment
October 15, 2024
8:00 am
ET
Read
Transpire Bio Strengthens Leadership Team with New Appointments to Lead Commercialization, Quality Assurance, and Manufacturing
October 15, 2024
8:00 am
ET
